021-51111890
购物车（）
sales@molnova.cn
Pazopanib hydrochloride
CAS No. 635702-64-6
Pazopanib hydrochloride ( GW786034;GW 786034;GW-786034 )
产品货号. M15407 CAS No. 635702-64-6
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 10MG | ￥389 | 有现货 |
|
| 25MG | ￥672 | 有现货 |
|
| 50MG | ￥786 | 有现货 |
|
| 100MG | ￥1158 | 有现货 |
|
| 200MG | ￥1944 | 有现货 |
|
| 500MG | ￥3062 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pazopanib hydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
-
产品描述A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively; also shows significant activity against the closely related RTKs PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 of 84, 74, 140, and 146 nM, respectively; potently inhibits VEGF-induced phosphorylation of VEGFR-2 in HUVEC cells with IC50 of 8 nM; inhibits in vivo tumor growth, increases MM cell apoptosis, decreases angiogenesis, and prolongs host survival in a xenograft model of human MM. Kidney Cancer Approved
-
同义词GW786034;GW 786034;GW-786034
-
通路Angiogenesis
-
靶点VEGFR
-
受体FGFR;PDGFR;VEGFR1;VEGFR2;VEGFR3
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number635702-64-6
-
分子量473.98
-
分子式C21H24ClN7O2S
-
纯度>98% (HPLC)
-
溶解度DMSO: 6.4 mg/mL (Need warming)
-
SMILESCC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
-
化学全称Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Podar K, et al. Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83.
2. Kumar R, et al. Mol Cancer Ther. 2007 Jul;6(7):2012-21.
3. Harris PA, et al. J Med Chem. 2008 Aug 14;51(15):4632-40.
4. Hurwitz HI, et al. Clin Cancer Res. 2009 Jun 15;15(12):4220-7.
2. Kumar R, et al. Mol Cancer Ther. 2007 Jul;6(7):2012-21.
3. Harris PA, et al. J Med Chem. 2008 Aug 14;51(15):4632-40.
4. Hurwitz HI, et al. Clin Cancer Res. 2009 Jun 15;15(12):4220-7.
产品手册
关联产品
-
Pazopanib
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
-
Ramucirumab
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.
-
SU14813 maleate
A broad-spectrum RTKs inhibitor with IC50 ranging from 2 to 50 nM for VEGFR-1, VEGFR-2, PDGFRs, KIT, FLT3, and CSF1R/FMS.
